Journal
DRUGS
Volume 80, Issue 9, Pages 905-912Publisher
ADIS INT LTD
DOI: 10.1007/s40265-020-01311-1
Keywords
-
Categories
Ask authors/readers for more resources
Isatuximab (isatuximab-irfc; Sarclisa(R)) is an IgG1 monoclonal antibody that binds to the glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells. It is being developed by Sanofi, under a license from Immunogen, for the treatment of haematological malignancies. In March 2020, intravenous isatuximab (in combination with pomalidomide and dexamethasone) was approved in the USA for the treatment of adult patients with multiple myeloma who have received >= 2 prior therapies, including lenalidomide and a proteasome inhibitor. Isatuximab has also received a positive opinion in the EU for the treatment of relapsed and refractory multiple myeloma. This article summarizes the milestones in the development of isatuximab leading to the first approval in the USA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available